相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial
Seung Cheol Shim et al.
RHEUMATOLOGY (2019)
Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54
Rieke Alten et al.
RMD OPEN (2019)
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
Mark C. Genovese et al.
ARTHRITIS RESEARCH & THERAPY (2019)
Quality of Life and Cost Study of Rheumatoid Arthritis Therapy With Biological Medicines
Vladimira V. Boyadzieva et al.
FRONTIERS IN PHARMACOLOGY (2018)
Similar Pharmacokinetics of the Adalimumab (Humira(A (R))) Biosimilar BI 695501 Whether Administered via Subcutaneous Autoinjector or Prefilled Syringe (VOLTAIRE(A (R))-AI and VOLTAIRE(A (R))-TAI): Phase 1, Randomized, Open-Label, Parallel-Group Trials
Steven Ramael et al.
RHEUMATOLOGY AND THERAPY (2018)
Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
Robert Moots et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
Vibeke Strand et al.
BIODRUGS (2017)
Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
Adeep Puri et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Combining Therapeutic Drug Monitoring with Biosimilars, a Strategy to Improve the Efficacy of Biologicals for Treating Inflammatory Bowel Diseases at an Affordable Cost
Ann Gils
DIGESTIVE DISEASES (2017)
Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
Paul W. Tebbey et al.
MABS (2015)
Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation
Pauline A. van Schouwenburg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis
Anke Vennegoor et al.
MULTIPLE SCLEROSIS JOURNAL (2013)
Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
Pauline A. van Schouwenburg et al.
NATURE REVIEWS RHEUMATOLOGY (2013)
Immunogenicity of biological therapeutics: from assay to patient
Charlotte Krieckaert et al.
CURRENT OPINION IN RHEUMATOLOGY (2012)
A Survey of Applications of Biological Products for Drug Interference of Immunogenicity Assays
Yow-Ming C. Wang et al.
PHARMACEUTICAL RESEARCH (2012)
Differential effect of drug interference in immunogenicity assays
Margreet H. Hart et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2011)
Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions
A. Vultaggio et al.
ALLERGY (2010)
A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients
Pauline A. van Schouwenburg et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis
C. J. van der Laken et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys
JR Rojas et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
分享论文
